BACKGROUND: We analyzed the results of combined heart-kidney transplantation (CHKTx) over a 10-year period. METHODS: Between September 1996 and May 2007 at Mayo Clinic, 12 patients (age 52 ± 12.2 years) underwent CHKTx as a simultaneous procedure in 10 recipients and as a staged procedure in two recipients with unstable hemodynamics after heart transplantation. RESULTS: There was no operative mortality. Patient survival rates for the CHKTx recipients at 1 and 3 months and 6 years were 91%, 83%, and 83% and did not differ from isolated heart transplantation (IHTx) recipients (97%, 95%, and 79%, P = 0.61). The freedom from cardiac allograft rejection (≥ grade 2) at 3 months was 73% for CHKTx and had not changed during further follow-up; for IHTx, freedom from rejection at 3 months and 1 and 6 years was 61%, 56%, and 42% (P = .08). Heart and renal allograft survival was 100% with and left ventricular ejection fraction 66% ± 8.4% and glomerular filtration rate 61 ± 25 at last follow-up. There were no signs of cardiac allograft vasculopathy in the CHKTx recipients. CONCLUSION: CHKTx yields favorable long-term outcome, with a low incidence of cardiac rejection and vasculopathy. Simultaneous CHKTx appears feasible, if hemodynamics is satisfactory. This approach expands the selection criteria for transplantation in patients with coexisting end-stage cardiac and renal disease. Published by Elsevier Inc.
BACKGROUND: We analyzed the results of combined heart-kidney transplantation (CHKTx) over a 10-year period. METHODS: Between September 1996 and May 2007 at Mayo Clinic, 12 patients (age 52 ± 12.2 years) underwent CHKTx as a simultaneous procedure in 10 recipients and as a staged procedure in two recipients with unstable hemodynamics after heart transplantation. RESULTS: There was no operative mortality. Patient survival rates for the CHKTx recipients at 1 and 3 months and 6 years were 91%, 83%, and 83% and did not differ from isolated heart transplantation (IHTx) recipients (97%, 95%, and 79%, P = 0.61). The freedom from cardiac allograft rejection (≥ grade 2) at 3 months was 73% for CHKTx and had not changed during further follow-up; for IHTx, freedom from rejection at 3 months and 1 and 6 years was 61%, 56%, and 42% (P = .08). Heart and renal allograft survival was 100% with and left ventricular ejection fraction 66% ± 8.4% and glomerular filtration rate 61 ± 25 at last follow-up. There were no signs of cardiac allograft vasculopathy in the CHKTx recipients. CONCLUSION: CHKTx yields favorable long-term outcome, with a low incidence of cardiac rejection and vasculopathy. Simultaneous CHKTx appears feasible, if hemodynamics is satisfactory. This approach expands the selection criteria for transplantation in patients with coexisting end-stage cardiac and renal disease. Published by Elsevier Inc.
Authors: Yan Topilsky; Eugenia Raichlin; Tal Hasin; Barry A Boilson; John A Schirger; Naveen L Pereira; Brooks S Edwards; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Manish J Gandhi; Simon Maltais; Soon J Park; Richard C Daly; Amir Lerman; Sudhir S Kushwaha Journal: Transplantation Date: 2013-03-27 Impact factor: 4.939
Authors: Jill Savla; Kimberly Y Lin; Madhura Pradhan; Rebecca L Ruebner; Rachel S Rogers; Somaly S Haskins; Anjali T Owens; Peter Abt; J William Gaynor; Robert E Shaddy; Joseph W Rossano Journal: J Am Heart Assoc Date: 2015-12-11 Impact factor: 5.501
Authors: Inga Melvinsdottir; David P Foley; Timothy Hess; Sverrir I Gunnarsson; Takushi Kohmoto; Joshua Hermsen; Maryl R Johnson; David Murray; Ravi Dhingra Journal: ESC Heart Fail Date: 2020-06-30
Authors: Oliver Beetz; Juliane Thies; Murat Avsar; Gerrit Grannas; Clara A Weigle; Fabio Ius; Michael Winkler; Christoph Bara; Nicolas Richter; Jürgen Klempnauer; Gregor Warnecke; Axel Haverich Journal: BMC Nephrol Date: 2021-07-09 Impact factor: 2.388
Authors: Oscar K Serrano; Heather L Kutzler; Caroline Rochon; Joseph A Radojevic; Michael T Lawlor; Jonathan A Hammond; Jason Gluck; Andrew D Feingold; Abhishek Jaiswal Journal: Transpl Infect Dis Date: 2020-07-01